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Abstract The expression and partial purification of recombi- 
nant 12 kDa B cell growth factor are reported. The polypeptide 
was derived from the genomic sequence of the gene (BCGF 1) 
which is here shown to be a single copy gene that localizes to 
human chromosome 16. When expressed as a glutathione 
S-transferase fusion protein in E. coli, the protein appears as a 
38 kDa polypeptide in Western blot analysis using a peptide 
antibody. The purified fusion protein stimulates the proliferation 
;ff activated human B cells in a dose-dependent manner, and the 
active site resides within the 104 carboxy-terminal amino acids. 
Fhe availability of biologically active recombinant 12 kDa B cell 
growth factor will enable its evaluation in B cell growth regula- 
tion, and provides a new means of in vitro culturing of human B 
fymphocytes. 
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I. Introduction 
Mature B lymphocytes express at least three different ypes 
of growth associated receptors, including surface immunoglob- 
ulins, transmembrane glycoproteins like CD40, and cytokine 
receptors, Some of these receptors, such as surface immuno- 
globulins and CD40, are constitutively expressed on B cells, 
whereas cytokine receptors are normally transiently expressed 
upon activation. In general, B cells require at least two stimuli 
for sustained growth. The first priming signal may be delivered 
by cross-linking surface immunoglobulin by antigen or anti- 
immunoglobulin antibodies, or by ligation of CD40 with its 
counter-receptor on activated T lymphocytes [1]. The second 
signal is mediated by cytokines. The cytokines that stimulate 
proliferation of activated B ceils include IL-2, 1L-4, IL-10, 
IL-13 and IL-14 [2-5]. Most studies concerning rowth regula- 
tion of human B cells by cytokines have been performed with 
well-characterized recombinant proteins; however, impure cy- 
tokines have also been used, leaving the biological significance 
of some of these factors open. 
One of the first cytokines that was shown to stimulate growth 
of activated mature B lymphocytes was a 12 kDa B cell growth 
factor (12 kDa BCGF) [6]. B cell growth factor activity was first 
demonstrated in 12,000-13,000 mol. wt. fractions of superna- 
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Abbreviations: BCGF, B cell growth factor; GST, glutathione S-trans- 
ferase. 
tants of lectin-activated T lymphocytes [6,7]. Later, the active 
protein (12 kDa BCGF) was purified to homogeneity [8]. The 
amino acid sequence of the protein was not determined, but 
using an expression cloning strategy Sharma and co-workers 
cloned the cDNA for 12 kDa BCGF [9]. A number of functions 
have been suggested for 12 kDa BCGF. This cytokine may 
stimulate growth of activated normal B lymphocytes, erve as 
a growth factor in B cell precursor acute lymphoblastic leuke- 
mia and in low-grade B cell lymphomas, or act as an autocrine 
growth factor in some cases of chronic lymphatic leukemia nd 
hairy cell leukemia [7,10 16]. 12 kDa BCGF has also been 
suggested to co-stimulate with IL-2 the proliferation of lym- 
phokine activated killer cells from children with acute lym- 
phoblastic leukemia and normal natural killer cells [17-19]. 
However, most of the data regarding 12 kDa BCGF has been 
obtained using commercial semi-purified preparations of the 
cytokine, and have not been verified with a recombinant factor. 
To obtain recombinant 12 kDa BCGF for functional studies 
we used PCR cloning to isolate the coding sequence for 12 kDa 
BCGF. During this attempt we identified a genomic open read- 
ing frame that is almost identical to the published cDNA of the 
12 kDa BCGF. The observed nucleotide changes cause a read- 
ing frame shift in 12 kDa BCGF polypeptide which results in 
a novel 37 amino acid amino-terminus. The nucleotide differ- 
ences are in concordance with those recently reported [20]. We 
have utilized this sequence data to further characterize the 
genomic sequence by localizing the gene (BCGF I) to chromo- 
some 16 and by expressing the encoded polypeptide as a gluta- 
thione S-transferase fusion protein. The recombinant protein 
stimulates the growth of activated B cells, suggesting that a 
bacterial expression system may prove useful in producing re- 
combinant 12 kDa BCGF for biological assays. 
2. Materials and methods 
2. I. Identification of the genomic sequence (BCGF 1 gene) 
Genomic high molecular weight DNA was extracted from white 
blood cells of two healthy donors and from the NK line 3.3 using 
standard techniques. PCR reactions were performed using primers P1 
and P2 with overhanging BamHI sites (Table 1). The sequences ofthese 
primers were deduced from the published sequence for 12 kDa BCGF 
[9]. The reactions were carried out according to the manufacturer's 
instructions (Perkin-Elmer/Roche Molecular Systems Inc., Branch- 
burg, N J, USA) under the following conditions: 95°C for 1 min, 55°C 
for 1 min and 72°C for 2 min for 30 cycles followed by 10 min of 
extension at 72°C. The reaction products were ethanol precipitated, 
and subsequently electrophoresed in 2% low-melting point agarose gels. 
The approximately 360 bp bands were excised from the gel, purified and 
digested with BamHI. The purified fragments were ligated into the 
dephosphorylated BamHl site of pBluescript SK- (Stratagene, CA, 
0014-5793195l$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
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USA) and cloned into XL-1 Blue strain ofE. coli. The plasmid DNAs 
were sequenced using the dideoxy method (Sequenase; USB, Cleveland, 
OH). The termination codon for the detected open reading frame 
(ORF) was ascertained by amplifying and sequencing PCR fragments 
that were generated using primers around the 3' and 5' ends of the ORF 
(P3 and P4). 
2.2. Southern blot analysis 
Genomic DNA from a healthy donor was restriction digested with 
BamHI and HindlII. The digested DNA was size fractionated by aga- 
rose gel-electrophoresis and transferred onto a nitrocellulose filter ac- 
cording to Southern [21]. The filter was hybridized with a randomly 
primed MaelII-AccI fragment of the sequence and washed under low- 
stringency conditions. The filter was exposed for autoradiography for
72 h. 
2.3. Chromosomal ssignment of BCGF 1 gene 
Two DNA panels of interspecies-specific somatic ell hybrids were 
used for the chromosomal ssignment. The panels were obtained from 
the Mutant Cell Repository of the Coriell Institute (Camden, NJ). The 
other panel was screened using PCR amplification and the reactions 
were carried out using primers P3 and P4. In each reaction 50 ng of 
template DNA was used and the cycle parameters were 95°C for I rain, 
60°C for 1 rain and 72°C for 2 min for 30 cycles followed by 10 rain 
at 72°C. The analysis was repeated four times. The other panel was 
screened using Southern blot analysis as described previously [22] using 
a randomly primed MaeIII-APAI fragment as a probe. 
2.4. Construction and purification of glutathione S-transJerase fusion 
proteins 
Three different fusion proteins were constructed by utilizing the 
predicted amino acid sequence of the genomic sequence of 12 kDa 
BCGF. All fusion proteins were constructed by cloning PCR amplified 
fragments with BamHI overhangs into the BamHI site of the pGEX-2T 
prokaryotic expression vector [23] (Pharmacia Biotech Norden AB, 
Sollentuna, Sweden). The primers ynthesized for different fusion pro- 
teins were P5 and P2 for GST-I/III, P6 and P2 for GST-II/III and P7 
and P2 for GST-III. All fusion constructs were sequenced and only 
unaltered clones were selected for fusion protein production. 
The fusion proteins were purified essentially as suggested in the 
manufacturer's manual (Pharmacia) with minor modifications. The 
fusion proteins GST-I/III and -II/III were purified as follows: 80 ml of 
overnight bacterial cultures were incubated for 2 h in 4 1 of prewarmed 
(37°C) LB media (ampicillin 50 pg/ml) with continuous haking. The 
cultures were then cooled to 28°C and the fusion protein expression was 
induced for 10 min with 0.1 mM IPTG. The cells were chilled in an 
ice-water bath for 30 min, and then pelleted at 6000 x g, resuspended 
in 40 ml of 10 mM Tris buffer, pH 8, containing 100 mM NaCI and 
treated with lysozyme at 0°C for 30 min. The cell suspension was 
sonicated for 1 rain and insoluble debris was removed by centrifugation 
(10,000 x g, 30 min). The supernatant was filtered through a 0.45 pm 
filter (Sartorius, G6ttingen, Germany) and applied to a glutathione- 
Sepharose column (Pharmacia) which had previously been equilibrated 
with 10 vols. of Tris buffer. The column was washed with 15 vols. of 
0.15 M NaCI, 0.01 M sodium phosphate (PBS), pH 7.4; 5 vols. of 1 M 
NaCI in PBS to remove bacterial LPS; and with 5 vols. of PBS. The 
fusion proteins were eluted with 5 vols. of 25 mM glutathione in PBS 
(pH 8). The presence of fusion proteins in the eluates was monitored 
by electrophoresis in 12% SDS-polyacrylamide g ls. The free glutathi- 
one was removed and the samples were concentrated by ultrafiltration 
using Centricon 30 concentrators (Amicon, MA, USA). The concen- 
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trated samples were analyzed by SDS-PAGE and tested for B cell 
growth factor activity in a thymidine incorporation assay. The fusion 
proteins GST-III and GST were purified essentially as described above, 
but as they were significantly more soluble than the other fusion pro- 
teins, smaller culture volumes (500 ml) and longer induction times 
(1 h) were used. 
2.5. B cell preparations and thymidine incorporation assays 
Human peripheral blood B ceils were purified from buffy coats 
(Finnish Red Cross Blood Transfusion Service) using magnetic CD19 
beads, a magnetic particle concentrator and Detachabead reagent ac- 
cording to manufacturer's instructions (Dynal A.S., Norway). The pu- 
rity of the B cell populations was determined by FACS analysis using 
monoclonal FITC-conjugated CD20 antibody (Becton-Dickinson, 
Erembogen, Belgium). Only over 96% pure B cell preparations were 
used in the growth assays. The B cell growth factor activity of different 
fusion proteins was tested using standard thymidine incorporation as- 
says. The cells were cultured as triplicates on round bottom 96-well 
microtiter plates (1 × 105 cells/well) in RPMI medium with 5% fetal calf 
serum and antibiotics, and they were stimulated for 4 days with anti- 
IgM beads (100 pg/ml; Bio-Rad Laboratories, CA, USA) and different 
concentrations of fusion protein eluates (expressed as percentage of 
total culture volume). During the last 6 h of culture the cells were pulsed 
with radioactive thymidine (1 pCi/well; Amersham International, 
Buckinghamshire, UK) and then harvested on filter papers. The 
amount of incorporated radioactive thymidine was measured using a 
beta-counter. 
2.6. Peptide synthesis 
The peptide NNQPKNLCSHFSFPTTYIKKERL was chosen from 
the hydrophilic region of the polypeptide and synthesized by a solid- 
phase method using Fmoc chemistry on an Applied Biosystems 430 A 
instrument. Cleavage and deprotection were carried out in TFA in the 
presence of scavengers (thioanisole, 1,2-ethanedithiol, phenol). The 
peptide was purified on HPLC using a C~8 reverse-phase column with 
an acetonitrile/TFA gradient. The structure was confirmed by FAB- 
mass spectrometry (Jeol SX-102 instrument). 
2. 7. Immunization, affinity purification of the antiserum and Western 
blot analysis 
The peptide was coupled to a carrier protein (Keyhole limpet hemo- 
cyanin) and used for immunization ofa New Zealand white rabbit. The 
immunization was carried out five times at 2-week intervals with 
Freund's adjuvant. Bleeding was done 2 weeks after the last injection. 
The antiserum was run through an affinity column containing the 
peptide coupled to thiopropyl-Sepharose 6B (Pharmacia). The column 
was eluted with 0.1 M glycine-HC1 buffer, pH 2.5, and the pooled Ig 
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Fig. 1. Southern blot analysis of the genomic sequence of 12 kDa 
BCGE Genomic DNA was digested with HindIII and BamHI and 
hybridized with the MaeIII-AccI fragment of the gene. 
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tig. 2. The alignment ofamino acid sequences of reported (lower, II) and previously published (upper, I) 12 kDa BCGF polypeptides. Vertical arrow 
i~ldicates the cleavage site of the predicted signal peptide and asterisk marks the site where the amino acid sequences become identical. Shaded boxes 
i~Ldicate sequences derived from ALU-like elements. These sequence data are available from EMBL/Genbank/DDJB under accession umber 
1~.I15530. 
I "actions were neutralized and dialyzed against water. Western blot 
~,nalysis was performed according to the manufacturer's in tructions 
~sing chemiluminescense detection of proteins (BM Chemilumines- 
ence Western blotting kit; Boehringer Mannheim, Germany). 
~. Resu l t s  and  d i scuss ion  
The cDNA coding for 12 kDa BCGF was published in 1987 
9], but data describing biological functions of the cytokine 
rove accumulated slowly as the recombinant factor has not 
!~een available. Here we describe the bacterial expression and 
~urification ofbiologically active 12 kDa BCGF by utilizing its 
~enomic sequence. Using PCR and primers deduced from the 
1~ublished cDNA sequence of the 12 kDa BCGF we identified 
t genomic open reading frame with four base differences from 
he published sequence: two base substitutions (119 C~G,  143 
.3~T)  and two single base deletions (176 C, 187 A). The first 
~ubstitution creates a stop codon at position 26 of the predicted 
imino acid sequence. However, with the two base deletions, a 
aovel 363 bp open reading frame is formed with an ATG start 
zodon at nucleotide position 77 of the 12 kDa BCGF sequence. 
Fhe possibility that the differences between our sequence and 
the published cDNA of 12 kDa BCGF would have resulted 
from PCR artefacts i negligible as the changes were consistent 
in three independent amplifications. Furthermore, during the 
final stages of this study the nucleotide sequence differences 
described here were also detected by another group, thus con- 
firming the authenticity of our sequence [20]. 
To verify that the obtained sequence represents he genomic 
sequence of 12 kDa BCGF and not a pseudogene ora member 
of a novel gene family, we performed genomic Southern blot 
analysis and PCR analysis of cross-species somatic ell hybrids. 
The Southern blot shows only a single band (Fig. 1), and PCR 
analysis of a panel of 24 cross-species somatic cell hybrids 
yielded a positive signal only from a hybrid which contained 
98% of human chromosome 16. The localization to human 
chromosome 16 was verified with Southern blot analysis of an 
other hybrid panel (Table 2). We are currently working on the 
exact localization of 12 kDa BCGFIBCGF 1 which may turn 
out to be interesting as chromosome 16 also contains other B 
cell associated genes, including a B cell maturation factor 
(BCMA,  16p 13.1), interleukin-4 receptor (16p 12) and genes for 
leukocyte integrin o-chains CD11 a, b and c (16pl 1). 
The polypeptide coded by the genomic sequence differs by 
37 amino-terminal amino acids from the published amino acid 
sequence of 12 kDa BCGF (Fig. 2). The amino-terminus con- 
tains characteristics of a signal peptide, and the algorithm 
Table 1 
Hybridization of human BCGF 1 gene with human/rodent somatic ell 
hybrids 
suggested to contain translated ALU sequences. One of these 
is a splice variant of primary biliary glycoprotein and another 
is RMSA- I ,  a presumably chromosomal protein [25-27]. 
To study possible mitogenic effects of the polypeptide and 
to start mapping the active domains we constructed three dif- 
ferent glutathione S-transferase fusion proteins and tested their 
effect on the growth of anti-IgM activated B lymphocytes: the 
full-length polypeptide (GST-I/III) and two truncation mutants 
(Fig. 3A). In the first mutant he 37 amino-terminal mino acids 
were truncated, leaving the part identical with the previously 
reported 12 kDa BCGF protein intact, The second mutant 
contains only the ALU-derived carboxy-terminal sequences 
(GST-III). As presented in Fig. 3B, both the full-length fusion 
protein (GST-I/III), and the anaino-terminally truncated one 
(GST-II/III) significantly increased the thymidine incorpora- 
tion of activated B cells when compared to B cells activated 
with anti-IgM beads alone (P < 0.02 and P < 0.002, respec- 
tively). On the other hand, the polypeptide derived from trans- 
lated ALU sequences (GST-III) or GST alone did not induce 
B cell growth. Fig. 4B demonstrates the dose-dependent re- 
sponse of anti-IgM-activated B cells to full-length polypeptide, 
and the lack of response to ALU-derived GST-III when stimu- 
lated with the same concentrations of fusion protein (as esti- 
mated from Coomassie blue stained gels; Fig. 4A) The growth- 
promoting activity of GST-I/I I I  was significant at a dilution of 
-> 1:100 (P < 0.007), corresponding to a specific concentration 
of approximately 10 ng/ml. The fusion proteins GST-I/I I I  and 
-II/III were relatively hydrophobic which resulted in co-purifi- 
cation of some bacterial proteins and endotoxin. The endotoxin 
content was reduced to a final concentration of < 2 ng/ml with 
1 M NaC1 and elution through a detoxigel column (Pierce) 
without affecting the growth factor activity (data not shown). 
It is also known that only relatively high concentrations of 
Hybrid BCGF 1 Chromosomes present 
NA07299 - 1,X 
GM10880 - 1,13,14 
NA10826B - 2 
NA10253 - 3 
NA10115 - 4 
NA10114 - 5 
NA10629 - 6 
NA10791 - 7 
NAI0156B - 8 
NAI0611 - 9 
NA10926B - 10 
NA10927A - 11 
NA10868 - 12 
NA10898 - 13 
NA10479 - 14 
NAII418 - 15 
NA10567 + 16 
NA10498 - 17 
NAll010 - 18 
NA10449 - 19 
NA10478 - 4,20 
NA10323 - 21 
NA10888 - 22 
NA06318B - X 
NA06317 - Y 
+ The presence of the BCGF 1 gene in the hybrids. 
A 
endotoxin are mitogenic to human B cells (-> 100/,tg/ml) [28]. 
Therefore, we concluded that the genomic sequence ncodes a 
polypeptide with BCGF activity. 
In summary, we have characterized and mapped the genomic 
locus coding for the 12 kDa BCGF (BCGF1), a potential B cell 
43 
1 2 3 4 5 
94 
67 
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Fig. 4. Polyacrylamide gel analysis of fusion proteins GST-I/III and GST-III and their effect on the growth of activated B lymphocytes. 
(A) Coomassie-blue stained lysates of uninduced bacteria (lane 1) and IPTG-induced (1.5 h) bacteria expressing GST-I/II! (lane 2) and GST-III (lane 
3) and purified fusion protein eluates of GST-I/III (lane 4) and GST-III (lane 5). The corresponding fusion proteins are marked by asterisks. Lanes 
6 and 7 show a Western blot analysis of the purified fusion proteins GST-I/IlI and GST-III, respectively. The peptide antibody was raised against 
a sequence present in GST-I/III but not in GST-III. 5/tl of eluates were loaded to the gels. (B) Thymidine incorporation of anti-IgM-activated B 
lymphocytes induced by different concentrations (% of total culture volume) of the same eluates. The results are presented as the average of five 
separate xperiments with standard error given. The asterisks represent significant differences in thymidine incorporation between cultures. 
(*P < 0.015, **P < 0.007, paired Student's t-test). 
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mitogen and growth factor of neoplastic B cells. Furthermore 
e have expressed the polypeptide as a GST fusion protein and 
shown that the purified recombinant factor stimulates the 
growth of activated B lymphocytes. The reported expression 
s!.,stem for recombinant 12 kDa BCGF will facilitate the study 
o r human B cell proliferation and may prove useful in develop- 
i ~g culture techniques of human B cells, for example for human 
a atibody production. 
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